LENZ Therapeutics, Inc. Common Stock (LENZ)
LENZ Therapeutics, Inc. (LENZ) is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders. The company specializes in designing targeted therapies that address unmet medical needs, leveraging cutting-edge research and technology to improve patient outcomes in areas such as neurodegenerative diseases and mental health conditions.
Company News
Lenz Therapeutics reported $5.0 million in Q2 2025 revenue from licensing deals, exceeding analyst expectations. The company is preparing for FDA review of LNZ100, an eye drop for presbyopia, with a decision expected by August 8, 2025. Despite increased operating expenses leading to a wider net loss, Lenz remains focused on commercial readiness.
Capstone data from Phase 3 CLARITY study to be presented
Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101. Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improveme...